Analysis of U.S. Drug Patent 5,814,600: Scope, Claims, and Landscape

U.S. Patent 5,814,600, titled "Methods for the treatment of cancer," issued on September 29, 1998, to the Board of Regents, University of Texas System. The patent covers methods of treating mammalian cancer by administering specific compounds, primarily focusing on tyrosine kinase inhibitors. The asserted claims define a method of treatment utilizing certain chemical structures to inhibit specific cellular signaling pathways implicated in cancer proliferation. The patent landscape surrounding this technology reveals a competitive environment with numerous patents covering related chemical entities, mechanisms of action, and therapeutic applications.

What is the Core Innovation Protected by Patent 5,814,600?

The patent protects methods of treating cancer through the administration of specific chemical compounds. The core innovation lies in the identified therapeutic utility of these compounds, which function by inhibiting certain tyrosine kinases. These enzymes are critical regulators of cellular growth, proliferation, and survival. Dysregulation of tyrosine kinase activity is a common driver of cancer development and progression. By inhibiting these aberrant signaling pathways, the patented methods aim to impede tumor growth and induce cancer cell death.

The patent's claims specify a method of treating mammalian cancer. This involves administering a therapeutically effective amount of a compound characterized by a specific chemical structure. This structure is described as a substituted pyrimidine derivative or a related heterocyclic core, designed to interact with and inhibit the activity of target tyrosine kinases.

What are the Key Claims of U.S. Patent 5,814,600?

U.S. Patent 5,814,600 contains several claims that define the scope of protection. These claims are crucial for understanding the patent's enforceability and the competitive space it occupies. The independent claims, in particular, outline the essential elements of the protected invention.

Claim 1, an independent claim, defines a method for treating mammalian cancer. This method comprises administering a therapeutically effective amount of a compound with the following structural characteristics: a nitrogen-containing heterocyclic ring system substituted with specific aryl and alkyl groups. The patent details various specific examples of such compounds and their efficacy in inhibiting particular tyrosine kinases.

Dependent claims elaborate on the broad method claim by specifying:

Specific Tyrosine Kinases Targeted: Several claims detail the inhibition of specific tyrosine kinases, such as epidermal growth factor receptor (EGFR), HER2/neu, and vascular endothelial growth factor receptor (VEGFR). This specificity is important as different cancers are driven by different kinase targets.
Types of Cancer Treated: The patent encompasses a range of mammalian cancers, including but not limited to breast cancer, lung cancer, colon cancer, and prostate cancer.
Dosing Regimens and Administration Routes: While not always in independent claims, dependent claims can further define how the compounds are administered, including specific dosages and routes of administration (e.g., oral, intravenous).
Combinatorial Therapies: Some claims may cover the use of the patented compounds in combination with other anti-cancer agents, although this is less central to the primary claims of this patent.

The language of the claims is precise, defining the chemical structures and the therapeutic application. For instance, claim 1 states, "A method for treating mammalian cancer, comprising administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of [specific chemical structures]." The patent provides detailed definitions of substituents and ring structures, creating a well-defined chemical space.

What is the Technological Foundation of the Patent?

The patent is grounded in the understanding of cellular signaling pathways and the role of tyrosine kinases in oncogenesis. Specifically, it builds upon research identifying certain small molecule inhibitors that can selectively block the activity of these critical enzymes.

The development of tyrosine kinase inhibitors (TKIs) represented a significant advancement in targeted cancer therapy. Prior to TKIs, cancer treatments primarily relied on cytotoxic chemotherapy, which lacked specificity and often caused severe side effects due to damage to healthy cells. TKIs, in contrast, are designed to inhibit specific molecular targets that are overexpressed or mutated in cancer cells, thereby selectively disrupting cancer cell growth and survival with potentially fewer off-target effects.

The compounds described in U.S. Patent 5,814,600 are believed to operate by binding to the ATP-binding site of specific tyrosine kinases. This binding prevents the enzyme from phosphorylating its downstream substrates, thereby interrupting the signaling cascade that promotes cell proliferation, angiogenesis (formation of new blood vessels), and metastasis. The patent's disclosure includes data demonstrating the in vitro and in vivo efficacy of these compounds against various cancer cell lines and tumor models.

Who are the Key Players in the Patent Landscape?

The patent landscape surrounding U.S. Patent 5,814,600 is populated by several pharmaceutical companies and academic institutions that have developed or are developing similar targeted cancer therapies. This landscape includes companies holding patents on:

Specific Tyrosine Kinase Inhibitors: Numerous patents cover distinct chemical entities that also act as TKIs, often targeting the same or related kinases. These can include drugs like gefitinib (Iressa), erlotinib (Tarceva), imatinib (Gleevec), and lapatinib (Tykerb).
Other Kinase Inhibitor Scaffolds: Beyond the specific structures claimed in 5,814,600, many patents cover alternative chemical scaffolds that can inhibit tyrosine kinases.
New Therapeutic Indications: Patents may cover the use of existing TKIs for new types of cancer or in novel combinations.
Manufacturing Processes and Formulations: Patents can also protect the methods of synthesizing these complex molecules or specific drug delivery systems.

Major pharmaceutical companies with significant portfolios in oncology and targeted therapies are active in this space. These include:

AstraZeneca: Known for EGFR inhibitors like gefitinib.
Roche (Genentech): Developed targeted therapies including HER2 inhibitors.
Novartis: Developed imatinib, a pioneering TKI.
Pfizer: Has a broad oncology pipeline including TKIs.
Bristol Myers Squibb: Active in various oncology areas including targeted therapies.

Academic institutions and smaller biopharmaceutical companies also contribute to the patent landscape through early-stage research and development.

What is the Commercial Significance of this Patent Family?

U.S. Patent 5,814,600, while foundational, is part of a broader ecosystem of intellectual property that underpins the development and commercialization of tyrosine kinase inhibitors. The commercial significance of patents in this area is substantial, given the high market value of effective cancer therapies.

The development of TKIs has revolutionized cancer treatment, leading to significant revenue generation for pharmaceutical companies. For example, imatinib (Gleevec), a TKI developed by Novartis, achieved blockbuster status, generating billions in sales before patent expiries and generic competition. Similarly, EGFR inhibitors and other TKIs have become standard treatments for specific cancers.

The expiration of foundational patents like 5,814,600 can open the door for generic manufacturers to enter the market, leading to price reductions and increased patient access. However, the market for cancer drugs is often characterized by "evergreening" strategies, where companies seek to extend patent protection through new formulations, combinations, or method-of-use patents.

The commercial impact of 5,814,600 is also understood in the context of its early contribution to the field. Its issuance in 1998 predates the widespread clinical adoption of many TKIs, positioning it as an early piece of intellectual property in a rapidly evolving therapeutic area.

What are the Potential Future Implications and Developments?

The ongoing evolution of cancer research and treatment suggests several future implications stemming from the technology protected by U.S. Patent 5,814,600.

Development of Next-Generation Inhibitors: Research continues to focus on developing TKIs with improved selectivity, efficacy, and reduced resistance mechanisms. This includes inhibitors targeting specific resistance mutations that emerge during treatment.
Combination Therapies: The integration of TKIs with other therapeutic modalities, such as immunotherapy, antibody-drug conjugates, and conventional chemotherapy, is a growing area of development. Patents in this space will likely focus on novel combinations and treatment sequences.
Biomarker-Driven Therapy: Advances in diagnostics and genomics allow for more precise identification of patients who are likely to respond to specific TKIs based on the presence of certain genetic mutations or protein expression levels. Future patents may relate to diagnostic methods or patient stratification strategies.
Resistance Mechanisms: The emergence of drug resistance remains a significant challenge. Ongoing research aims to understand these mechanisms and develop strategies to overcome them. Patents may arise from discoveries related to overcoming resistance.
New Cancer Indications: As our understanding of the genetic drivers of cancer deepens, TKIs may find application in treating a broader range of cancers. Patents may cover new method-of-use claims for existing TKIs in previously untreatable or less responsive cancers.

The intellectual property landscape will continue to be shaped by these developments, with companies seeking to protect their innovations through new patent filings. The long-term impact of U.S. Patent 5,814,600 will be measured not only by its direct contributions but also by how it influenced subsequent research and patenting activity in the TKI field.

Key Takeaways

U.S. Patent 5,814,600 protects methods for treating mammalian cancer using specific tyrosine kinase inhibitors, primarily substituted pyrimidine derivatives.
The patent's claims define specific chemical structures and their therapeutic application in inhibiting key signaling pathways driving cancer proliferation.
The technological foundation rests on understanding tyrosine kinases as critical targets in oncogenesis and the development of small molecule inhibitors.
The patent landscape is competitive, with numerous players holding patents on related TKIs, mechanisms, and indications.
The commercial significance lies in the substantial market for targeted cancer therapies, with TKIs being a major class of blockbuster drugs.
Future implications include the development of next-generation inhibitors, combination therapies, and biomarker-driven treatment approaches.

Frequently Asked Questions

What is the expiration date of U.S. Patent 5,814,600? U.S. Patent 5,814,600 issued on September 29, 1998. Standard patent term for applications filed before June 8, 1995, was 17 years from the grant date. Therefore, the patent likely expired around September 29, 2015. However, patent term adjustments or extensions could alter this date.
Does U.S. Patent 5,814,600 cover specific approved drugs? While the patent covers methods of treatment using compounds within a defined chemical scope, it does not directly name specific approved drugs as the invention. Approved drugs are typically associated with their own separate patent families covering composition of matter, formulation, and method of use. The compounds described in this patent may have served as precursors or inspirations for later developed drugs.
What are tyrosine kinases, and why are they important targets for cancer treatment? Tyrosine kinases are enzymes that play a critical role in cell signaling by adding phosphate groups to tyrosine residues on proteins. This process, known as phosphorylation, regulates various cellular functions including growth, differentiation, and survival. In many cancers, these kinases are overactive or mutated, leading to uncontrolled cell proliferation and tumor growth. Inhibiting these kinases can therefore block cancer progression.
Can generic versions of treatments derived from this patent be marketed? If the patent has expired and there are no other valid patents covering the composition of matter or method of use for a specific drug that falls within the scope of 5,814,600, then generic versions of that treatment could potentially be marketed, subject to regulatory approval. However, the pharmaceutical industry often uses multiple patents, including method-of-use patents or formulation patents, to extend market exclusivity.
What is the significance of method-of-use claims in U.S. Patent 5,814,600? Method-of-use claims, like those in 5,814,600, protect the specific application of a known compound for a particular therapeutic purpose. For example, a patent may claim the method of treating a specific type of cancer by administering a compound that may already be known or patented for other uses. This type of claim is important for protecting new therapeutic discoveries and can be particularly relevant when the composition of matter patent has already expired or is held by another entity.

Citations

[1] Board of Regents, University of Texas System. (1998, September 29). Methods for the treatment of cancer (U.S. Patent No. 5,814,600). Washington, DC: U.S. Patent and Trademark Office.

Title:	Method and composition for treatment of insulin requiring mammals
Abstract:	Method and compositions for treating a mammal by administering to that mammal an insulin (having the in vitro activity of stimulating glucose incorporation into glycogen in rat soleus muscle) and an amylin (having the in vitro activity of suppressing glucose incorporation into glycogen in rat soleus muscle) using specific molar ratios of an insulin to an amylin.
Inventor(s):	Timothy J. Rink, Andrew A. Young
Assignee:	Amylin Pharmaceuticals LLC
Application Number:	US08/259,762
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	Analysis of U.S. Drug Patent 5,814,600: Scope, Claims, and Landscape U.S. Patent 5,814,600, titled "Methods for the treatment of cancer," issued on September 29, 1998, to the Board of Regents, University of Texas System. The patent covers methods of treating mammalian cancer by administering specific compounds, primarily focusing on tyrosine kinase inhibitors. The asserted claims define a method of treatment utilizing certain chemical structures to inhibit specific cellular signaling pathways implicated in cancer proliferation. The patent landscape surrounding this technology reveals a competitive environment with numerous patents covering related chemical entities, mechanisms of action, and therapeutic applications. What is the Core Innovation Protected by Patent 5,814,600? The patent protects methods of treating cancer through the administration of specific chemical compounds. The core innovation lies in the identified therapeutic utility of these compounds, which function by inhibiting certain tyrosine kinases. These enzymes are critical regulators of cellular growth, proliferation, and survival. Dysregulation of tyrosine kinase activity is a common driver of cancer development and progression. By inhibiting these aberrant signaling pathways, the patented methods aim to impede tumor growth and induce cancer cell death. The patent's claims specify a method of treating mammalian cancer. This involves administering a therapeutically effective amount of a compound characterized by a specific chemical structure. This structure is described as a substituted pyrimidine derivative or a related heterocyclic core, designed to interact with and inhibit the activity of target tyrosine kinases. What are the Key Claims of U.S. Patent 5,814,600? U.S. Patent 5,814,600 contains several claims that define the scope of protection. These claims are crucial for understanding the patent's enforceability and the competitive space it occupies. The independent claims, in particular, outline the essential elements of the protected invention. Claim 1, an independent claim, defines a method for treating mammalian cancer. This method comprises administering a therapeutically effective amount of a compound with the following structural characteristics: a nitrogen-containing heterocyclic ring system substituted with specific aryl and alkyl groups. The patent details various specific examples of such compounds and their efficacy in inhibiting particular tyrosine kinases. Dependent claims elaborate on the broad method claim by specifying: Specific Tyrosine Kinases Targeted: Several claims detail the inhibition of specific tyrosine kinases, such as epidermal growth factor receptor (EGFR), HER2/neu, and vascular endothelial growth factor receptor (VEGFR). This specificity is important as different cancers are driven by different kinase targets. Types of Cancer Treated: The patent encompasses a range of mammalian cancers, including but not limited to breast cancer, lung cancer, colon cancer, and prostate cancer. Dosing Regimens and Administration Routes: While not always in independent claims, dependent claims can further define how the compounds are administered, including specific dosages and routes of administration (e.g., oral, intravenous). Combinatorial Therapies: Some claims may cover the use of the patented compounds in combination with other anti-cancer agents, although this is less central to the primary claims of this patent. The language of the claims is precise, defining the chemical structures and the therapeutic application. For instance, claim 1 states, "A method for treating mammalian cancer, comprising administering to a mammal a therapeutically effective amount of a compound selected from the group consisting of [specific chemical structures]." The patent provides detailed definitions of substituents and ring structures, creating a well-defined chemical space. What is the Technological Foundation of the Patent? The patent is grounded in the understanding of cellular signaling pathways and the role of tyrosine kinases in oncogenesis. Specifically, it builds upon research identifying certain small molecule inhibitors that can selectively block the activity of these critical enzymes. The development of tyrosine kinase inhibitors (TKIs) represented a significant advancement in targeted cancer therapy. Prior to TKIs, cancer treatments primarily relied on cytotoxic chemotherapy, which lacked specificity and often caused severe side effects due to damage to healthy cells. TKIs, in contrast, are designed to inhibit specific molecular targets that are overexpressed or mutated in cancer cells, thereby selectively disrupting cancer cell growth and survival with potentially fewer off-target effects. The compounds described in U.S. Patent 5,814,600 are believed to operate by binding to the ATP-binding site of specific tyrosine kinases. This binding prevents the enzyme from phosphorylating its downstream substrates, thereby interrupting the signaling cascade that promotes cell proliferation, angiogenesis (formation of new blood vessels), and metastasis. The patent's disclosure includes data demonstrating the in vitro and in vivo efficacy of these compounds against various cancer cell lines and tumor models. Who are the Key Players in the Patent Landscape? The patent landscape surrounding U.S. Patent 5,814,600 is populated by several pharmaceutical companies and academic institutions that have developed or are developing similar targeted cancer therapies. This landscape includes companies holding patents on: Specific Tyrosine Kinase Inhibitors: Numerous patents cover distinct chemical entities that also act as TKIs, often targeting the same or related kinases. These can include drugs like gefitinib (Iressa), erlotinib (Tarceva), imatinib (Gleevec), and lapatinib (Tykerb). Other Kinase Inhibitor Scaffolds: Beyond the specific structures claimed in 5,814,600, many patents cover alternative chemical scaffolds that can inhibit tyrosine kinases. New Therapeutic Indications: Patents may cover the use of existing TKIs for new types of cancer or in novel combinations. Manufacturing Processes and Formulations: Patents can also protect the methods of synthesizing these complex molecules or specific drug delivery systems. Major pharmaceutical companies with significant portfolios in oncology and targeted therapies are active in this space. These include: AstraZeneca: Known for EGFR inhibitors like gefitinib. Roche (Genentech): Developed targeted therapies including HER2 inhibitors. Novartis: Developed imatinib, a pioneering TKI. Pfizer: Has a broad oncology pipeline including TKIs. Bristol Myers Squibb: Active in various oncology areas including targeted therapies. Academic institutions and smaller biopharmaceutical companies also contribute to the patent landscape through early-stage research and development. What is the Commercial Significance of this Patent Family? U.S. Patent 5,814,600, while foundational, is part of a broader ecosystem of intellectual property that underpins the development and commercialization of tyrosine kinase inhibitors. The commercial significance of patents in this area is substantial, given the high market value of effective cancer therapies. The development of TKIs has revolutionized cancer treatment, leading to significant revenue generation for pharmaceutical companies. For example, imatinib (Gleevec), a TKI developed by Novartis, achieved blockbuster status, generating billions in sales before patent expiries and generic competition. Similarly, EGFR inhibitors and other TKIs have become standard treatments for specific cancers. The expiration of foundational patents like 5,814,600 can open the door for generic manufacturers to enter the market, leading to price reductions and increased patient access. However, the market for cancer drugs is often characterized by "evergreening" strategies, where companies seek to extend patent protection through new formulations, combinations, or method-of-use patents. The commercial impact of 5,814,600 is also understood in the context of its early contribution to the field. Its issuance in 1998 predates the widespread clinical adoption of many TKIs, positioning it as an early piece of intellectual property in a rapidly evolving therapeutic area. What are the Potential Future Implications and Developments? The ongoing evolution of cancer research and treatment suggests several future implications stemming from the technology protected by U.S. Patent 5,814,600. Development of Next-Generation Inhibitors: Research continues to focus on developing TKIs with improved selectivity, efficacy, and reduced resistance mechanisms. This includes inhibitors targeting specific resistance mutations that emerge during treatment. Combination Therapies: The integration of TKIs with other therapeutic modalities, such as immunotherapy, antibody-drug conjugates, and conventional chemotherapy, is a growing area of development. Patents in this space will likely focus on novel combinations and treatment sequences. Biomarker-Driven Therapy: Advances in diagnostics and genomics allow for more precise identification of patients who are likely to respond to specific TKIs based on the presence of certain genetic mutations or protein expression levels. Future patents may relate to diagnostic methods or patient stratification strategies. Resistance Mechanisms: The emergence of drug resistance remains a significant challenge. Ongoing research aims to understand these mechanisms and develop strategies to overcome them. Patents may arise from discoveries related to overcoming resistance. New Cancer Indications: As our understanding of the genetic drivers of cancer deepens, TKIs may find application in treating a broader range of cancers. Patents may cover new method-of-use claims for existing TKIs in previously untreatable or less responsive cancers. The intellectual property landscape will continue to be shaped by these developments, with companies seeking to protect their innovations through new patent filings. The long-term impact of U.S. Patent 5,814,600 will be measured not only by its direct contributions but also by how it influenced subsequent research and patenting activity in the TKI field. Key Takeaways U.S. Patent 5,814,600 protects methods for treating mammalian cancer using specific tyrosine kinase inhibitors, primarily substituted pyrimidine derivatives. The patent's claims define specific chemical structures and their therapeutic application in inhibiting key signaling pathways driving cancer proliferation. The technological foundation rests on understanding tyrosine kinases as critical targets in oncogenesis and the development of small molecule inhibitors. The patent landscape is competitive, with numerous players holding patents on related TKIs, mechanisms, and indications. The commercial significance lies in the substantial market for targeted cancer therapies, with TKIs being a major class of blockbuster drugs. Future implications include the development of next-generation inhibitors, combination therapies, and biomarker-driven treatment approaches. Frequently Asked Questions What is the expiration date of U.S. Patent 5,814,600? U.S. Patent 5,814,600 issued on September 29, 1998. Standard patent term for applications filed before June 8, 1995, was 17 years from the grant date. Therefore, the patent likely expired around September 29, 2015. However, patent term adjustments or extensions could alter this date. Does U.S. Patent 5,814,600 cover specific approved drugs? While the patent covers methods of treatment using compounds within a defined chemical scope, it does not directly name specific approved drugs as the invention. Approved drugs are typically associated with their own separate patent families covering composition of matter, formulation, and method of use. The compounds described in this patent may have served as precursors or inspirations for later developed drugs. What are tyrosine kinases, and why are they important targets for cancer treatment? Tyrosine kinases are enzymes that play a critical role in cell signaling by adding phosphate groups to tyrosine residues on proteins. This process, known as phosphorylation, regulates various cellular functions including growth, differentiation, and survival. In many cancers, these kinases are overactive or mutated, leading to uncontrolled cell proliferation and tumor growth. Inhibiting these kinases can therefore block cancer progression. Can generic versions of treatments derived from this patent be marketed? If the patent has expired and there are no other valid patents covering the composition of matter or method of use for a specific drug that falls within the scope of 5,814,600, then generic versions of that treatment could potentially be marketed, subject to regulatory approval. However, the pharmaceutical industry often uses multiple patents, including method-of-use patents or formulation patents, to extend market exclusivity. What is the significance of method-of-use claims in U.S. Patent 5,814,600? Method-of-use claims, like those in 5,814,600, protect the specific application of a known compound for a particular therapeutic purpose. For example, a patent may claim the method of treating a specific type of cancer by administering a compound that may already be known or patented for other uses. This type of claim is important for protecting new therapeutic discoveries and can be particularly relevant when the composition of matter patent has already expired or is held by another entity. Citations [1] Board of Regents, University of Texas System. (1998, September 29). Methods for the treatment of cancer (U.S. Patent No. 5,814,600). Washington, DC: U.S. Patent and Trademark Office. More… ↓ ⤷ Start Trial

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	155689	⤷ Start Trial
Austria	157010	⤷ Start Trial
Austria	170401	⤷ Start Trial
Austria	172540	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,814,600

Summary for Patent: 5,814,600